

NEXT SCIENCE®

ASX ANNOUNCEMENT / MEDIA RELEASE
ASX: (NXS)

Letter to shareholders

Sydney Australia Monday, 24 July 2023: Next Science Limited (ASX: NXS) (**Next Science or Company**), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, attaches a letter which will be distributed to shareholders today, 24 July 2023.

Further Information:

Martyn Jacobs

Head of Investor Relations

Phone: +61 412 785 180

Email: mjacobs@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

Next Science Limited ACN 622 382 549

Level 14 Australia Square
264 - 278 George Street
Sydney NSW 2000
www.nextscience.com

HEALING PEOPLE SAVING LIVES

NEXT SCIENCE®

24 July 2023

Dear Shareholder,

Next Science Limited (**Next Science or Company**) is pleased to advise of the launch of a new Next Science Investor Hub.

The Next Science Investor Hub is a dedicated platform for investors to learn more about our business and latest activities as we continue to grow and build awareness within the healthcare industry.

In addition to Next Science ASX announcements, the Next Science Investor Hub will contain supplementary content including videos, interviews, media coverage, and other information about the Company and its products.

Next Science encourages shareholders and other interested stakeholders to sign-up to the Next Science Investor Hub to stay up to date with Next Science's latest news and interact with Next Science through the Q&A function. Subscribers to the Next Science Investor Hub may also receive invitations to exclusive events, and other opportunities, from time to time.

We are fortunate to have an engaged and passionate shareholder base that cares immensely about reducing biofilm-based infections in human health. As we continue to build awareness and grow our business, we look forward to interacting with our shareholders and other stakeholders through our Next Science Investor Hub.

How to sign-up to the Next Science Investor Hub

1. Navigate to <https://investorhub.nextscience.com/welcome> or scan the QR code below with your smartphone device and this will take you to the Next Science Investor Hub sign-up page.
2. Follow the prompts to sign up for an Investor Hub account.
3. Complete your account profile.



If you have any questions regarding the Investor Hub, please contact our Head of Investor Relations, Martyn Jacobs, on +61 412 785 180 or at mjacobs@nextscience.com

Yours sincerely

A handwritten signature in black ink, appearing to read "I.V. Hall". The signature is fluid and cursive, with a long horizontal stroke at the end.

I.V. Hall
Managing Director and CEO
Next Science Limited

Next Science Limited ACN 622 382 549
Level 14 Australia Square
264 - 278 George Street
Sydney NSW 2000
www.nextscience.com

HEALING PEOPLE SAVING LIVES